News 2012
Breast Cancer New Drug: OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
Breast Cancer New Drug:OBI-822/821 received Taiwan FDA Approval for entering Phase III trial
DIFICID (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of CDAD
DIFICID® (Fidaxomicin) Approved by Taiwan Department of Health for the Treatment of Clostridium Difficile Associated Diarrhea (CDAD) TAIPEI, 20 July 2012 OBI Pharma, Inc. announced today that DIFICID® (Fidaxomicin) has …